利用Vnn1泛酰巯基乙胺酶通路促进结肠炎中短链脂肪酸产生和黏膜保护
研究通过结肠活检RNA测序和VIVA转基因小鼠模型,发现Vnn1在炎症结肠上皮细胞过表达,其泛酰巯基乙胺酶活性可增强辅酶A再生、促进微生物依赖的短链脂肪酸(主要为丁酸)产生,从而保护黏膜抵抗结肠炎损伤,并鉴定尿中硫酸吲哚酚为Vnn1过表达的生物标志物。
要点
- VNN1在结肠上皮细胞过表达与IBD严重程度相关,小鼠中Vnn1过表达可抵抗实验性结肠炎。
- Vnn1泛酰巯基乙胺酶活性增强辅酶A再生和代谢适应,促进微生物依赖的短链脂肪酸(主要为丁酸)产生。
- 给予底物泛酰巯基乙胺或产物可模拟保护表型,尿硫酸吲哚酚为Vnn1过表达的生物标志物。
核心结论
- 小鼠和人类结肠炎中Vnn1/VNN1的诱导是加强黏膜屏障的代偿机制,增强维生素B5驱动的代谢应可改善黏膜愈合,并可能提高抗炎治疗的疗效。
研究设计与样本
- 对按临床严重程度和治疗方式分层的IBD患者结肠活检样本进行RNA测序研究。
- 构建在肠上皮细胞特异性过表达Vnn1的VIVA小鼠转基因模型,并探索其对结肠炎的易感性。
- 通过给予Vnn1衍生物开发Vnn1过表达的药理模拟。
主要发现
- 结肠上皮细胞VNN1过表达与IBD严重程度相关。
- VIVA小鼠对实验诱导的结肠炎具有抵抗性。
- Vnn1的泛酰巯基乙胺酶活性在结肠中具有细胞保护作用:增强辅酶A再生和结肠上皮细胞的代谢适应。
- Vnn1活性促进微生物依赖的短链脂肪酸产生,主要为丁酸,丁酸被证明可调节黏膜能量代谢,且在IBD患者中降低。
- 在诱导结肠炎前用底物(泛酰巯基乙胺)或泛酰巯基乙胺酶活性产物治疗对照小鼠可重现这种促愈合表型。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the management of patients with IBD, there is a need to identify prognostic markers and druggable biological pathways to improve mucosal repair and probe the efficacy of tumour necrosis factor alpha biologics. Vnn1 is a pantetheinase that degrades pantetheine to pantothenate (vitamin B5, a precursor of coenzyme A (CoA) biosynthesis) and cysteamine. Vnn1 is overexpressed by inflamed colonocytes. We investigated its contribution to the tolerance of the intestinal mucosa to colitis-induced injury. DESIGN: We performed an RNA sequencing study on colon biopsy samples from patients with IBD stratified according to clinical severity and modalities of treatment. We generated the VIVA mouse transgenic model, which specifically overexpresses Vnn1 on intestinal epithelial cells and explored its susceptibility to colitis. We developed a pharmacological mimicry of Vnn1 overexpression by administration of Vnn1 derivatives. RESULTS: VNN1 overexpression on colonocytes correlates with IBD severity. VIVA mice are resistant to experimentally induced colitis. The pantetheinase activity of Vnn1 is cytoprotective in colon: it enhances CoA regeneration and metabolic adaptation of colonocytes; it favours microbiota-dependent production of short chain fatty acids and mostly butyrate, shown to regulate mucosal energetics and to be reduced in patients with IBD. This prohealing phenotype is recapitulated by treating control mice with the substrate (pantethine) or the products of pantetheinase activity prior to induction of colitis. In severe IBD, the protection conferred by the high induction of VNN1 might be compromised because its enzymatic activity may be limited by lack of available substrates. In addition, we identify the elevation of indoxyl sulfate in urine as a biomarker of Vnn1 overexpression, also detected in patients with IBD. CONCLUSION: The induction of Vnn1/VNN1 during colitis in mouse and human is a compensatory mechanism to reinforce the mucosal barrier. Therefore, enhancement of vitamin B5-driven metabolism should improve mucosal healing and might increase the efficacy of anti-inflammatory therapy.
引用
- Millet V, Gensollen T, Maltese M, et al. Harnessing the Vnn1 pantetheinase pathway boosts short chain fatty acids production and mucosal protection in colitis. Gut. 2022. PMID: 36175116. doi:10.1136/gutjnl-2021-325792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。